XBiotech Inc.

For the period ended Dec 31, 2024. Filed Mar 18, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Mar 18, 2025

XBIT$1.91+1.1%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Balance Sheets

(in thousands, except share data)

	December 31, 2024	December 31, 2023
Assets
Current assets:
Cash and cash equivalents	$172,677	$200,023
Accrued interest receivable	700	860
Income tax receivable	158	75
Prepaid expenses and other current assets	1,032	760
Total current assets	174,567	201,718
Property and equipment, net	24,526	24,897
Total assets	$199,093	$226,615
Liabilities and shareholders’ equity
Current liabilities:
Accounts payable	$2,223	$2,516
Accrued expenses	2,632	3,501
Income tax payable	-	83
Convertible loan, related party	10,000	-
Convertible loan, third party	250	-
Total current liabilities	15,105	6,100
Long-term liabilities:
Income tax payable	1,720	1,669
Total liabilities	16,825	7,769
Shareholders’ equity:
Preferred stock, no par value, unlimited shares authorized, no shares outstanding	-	-
Common stock, no par value, unlimited shares authorized, 30,487,731 and 30,436,964 shares issued and outstanding at December 31, 2024 and December 31, 2023, respectively	273,105	271,152
Accumulated deficit	(90,837)	(52,306)
Total shareholders’ equity	182,268	218,846
Total liabilities and shareholders’ equity	$199,093	$226,615

See accompanying notes to consolidated financial statements.

Consolidated Statements of Operations

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.